Engineering T cell receptor fusion proteins using nonviral CRISPR/Cas9 genome editing for cancer immunotherapy
Manufacture of chimeric antigen receptor (CAR)‐T cells usually involves the use of viral delivery systems to achieve high transgene expression. However, it can be costly and may result in random integration of the CAR into the genome, creating several disadvantages including variation in transgene e...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10658519/ https://www.ncbi.nlm.nih.gov/pubmed/38023726 http://dx.doi.org/10.1002/btm2.10571 |
_version_ | 1785137435968012288 |
---|---|
author | Shu, Runzhe Hammett, Maree Evtimov, Vera Pupovac, Aleta Nguyen, Nhu‐Y Islam, Rasa Zhuang, Junli Lee, Seyeong Kang, Tae‐hun Lee, Kyujun Nisbet, Ian Hudson, Peter Lee, Jae Young Boyd, Richard Trounson, Alan |
author_facet | Shu, Runzhe Hammett, Maree Evtimov, Vera Pupovac, Aleta Nguyen, Nhu‐Y Islam, Rasa Zhuang, Junli Lee, Seyeong Kang, Tae‐hun Lee, Kyujun Nisbet, Ian Hudson, Peter Lee, Jae Young Boyd, Richard Trounson, Alan |
author_sort | Shu, Runzhe |
collection | PubMed |
description | Manufacture of chimeric antigen receptor (CAR)‐T cells usually involves the use of viral delivery systems to achieve high transgene expression. However, it can be costly and may result in random integration of the CAR into the genome, creating several disadvantages including variation in transgene expression, functional gene silencing and potential oncogenic transformation. Here, we optimized the method of nonviral, CRISPR/Cas9 genome editing using large donor DNA delivery, knocked‐in an anti‐tumor single chain variable fragment (scFv) into the N‐terminus of CD3ε and efficiently generated fusion protein (FP) T cells. These cells displayed FP integration within the TCR/CD3 complex, lower variability in gene expression compared to CAR‐T cells and good cell expansion after transfection. CD3ε FP T cells were predominantly CD8(+) effector memory T cells, and exhibited anti‐tumor activity in vitro and in vivo. Dual targeting FP T cells were also generated through the incorporation of scFvs into other CD3 subunits and CD28. Compared to viral‐based methods, this method serves as an alternative and versatile way of generating T cells with tumor‐targeting receptors for cancer immunotherapy. |
format | Online Article Text |
id | pubmed-10658519 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley & Sons, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-106585192023-07-10 Engineering T cell receptor fusion proteins using nonviral CRISPR/Cas9 genome editing for cancer immunotherapy Shu, Runzhe Hammett, Maree Evtimov, Vera Pupovac, Aleta Nguyen, Nhu‐Y Islam, Rasa Zhuang, Junli Lee, Seyeong Kang, Tae‐hun Lee, Kyujun Nisbet, Ian Hudson, Peter Lee, Jae Young Boyd, Richard Trounson, Alan Bioeng Transl Med Regular Issue Articles Manufacture of chimeric antigen receptor (CAR)‐T cells usually involves the use of viral delivery systems to achieve high transgene expression. However, it can be costly and may result in random integration of the CAR into the genome, creating several disadvantages including variation in transgene expression, functional gene silencing and potential oncogenic transformation. Here, we optimized the method of nonviral, CRISPR/Cas9 genome editing using large donor DNA delivery, knocked‐in an anti‐tumor single chain variable fragment (scFv) into the N‐terminus of CD3ε and efficiently generated fusion protein (FP) T cells. These cells displayed FP integration within the TCR/CD3 complex, lower variability in gene expression compared to CAR‐T cells and good cell expansion after transfection. CD3ε FP T cells were predominantly CD8(+) effector memory T cells, and exhibited anti‐tumor activity in vitro and in vivo. Dual targeting FP T cells were also generated through the incorporation of scFvs into other CD3 subunits and CD28. Compared to viral‐based methods, this method serves as an alternative and versatile way of generating T cells with tumor‐targeting receptors for cancer immunotherapy. John Wiley & Sons, Inc. 2023-07-10 /pmc/articles/PMC10658519/ /pubmed/38023726 http://dx.doi.org/10.1002/btm2.10571 Text en © 2023 Cartherics. Bioengineering & Translational Medicine published by Wiley Periodicals LLC on behalf of the American Institute of Chemical Engineers. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Regular Issue Articles Shu, Runzhe Hammett, Maree Evtimov, Vera Pupovac, Aleta Nguyen, Nhu‐Y Islam, Rasa Zhuang, Junli Lee, Seyeong Kang, Tae‐hun Lee, Kyujun Nisbet, Ian Hudson, Peter Lee, Jae Young Boyd, Richard Trounson, Alan Engineering T cell receptor fusion proteins using nonviral CRISPR/Cas9 genome editing for cancer immunotherapy |
title | Engineering T cell receptor fusion proteins using nonviral CRISPR/Cas9 genome editing for cancer immunotherapy |
title_full | Engineering T cell receptor fusion proteins using nonviral CRISPR/Cas9 genome editing for cancer immunotherapy |
title_fullStr | Engineering T cell receptor fusion proteins using nonviral CRISPR/Cas9 genome editing for cancer immunotherapy |
title_full_unstemmed | Engineering T cell receptor fusion proteins using nonviral CRISPR/Cas9 genome editing for cancer immunotherapy |
title_short | Engineering T cell receptor fusion proteins using nonviral CRISPR/Cas9 genome editing for cancer immunotherapy |
title_sort | engineering t cell receptor fusion proteins using nonviral crispr/cas9 genome editing for cancer immunotherapy |
topic | Regular Issue Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10658519/ https://www.ncbi.nlm.nih.gov/pubmed/38023726 http://dx.doi.org/10.1002/btm2.10571 |
work_keys_str_mv | AT shurunzhe engineeringtcellreceptorfusionproteinsusingnonviralcrisprcas9genomeeditingforcancerimmunotherapy AT hammettmaree engineeringtcellreceptorfusionproteinsusingnonviralcrisprcas9genomeeditingforcancerimmunotherapy AT evtimovvera engineeringtcellreceptorfusionproteinsusingnonviralcrisprcas9genomeeditingforcancerimmunotherapy AT pupovacaleta engineeringtcellreceptorfusionproteinsusingnonviralcrisprcas9genomeeditingforcancerimmunotherapy AT nguyennhuy engineeringtcellreceptorfusionproteinsusingnonviralcrisprcas9genomeeditingforcancerimmunotherapy AT islamrasa engineeringtcellreceptorfusionproteinsusingnonviralcrisprcas9genomeeditingforcancerimmunotherapy AT zhuangjunli engineeringtcellreceptorfusionproteinsusingnonviralcrisprcas9genomeeditingforcancerimmunotherapy AT leeseyeong engineeringtcellreceptorfusionproteinsusingnonviralcrisprcas9genomeeditingforcancerimmunotherapy AT kangtaehun engineeringtcellreceptorfusionproteinsusingnonviralcrisprcas9genomeeditingforcancerimmunotherapy AT leekyujun engineeringtcellreceptorfusionproteinsusingnonviralcrisprcas9genomeeditingforcancerimmunotherapy AT nisbetian engineeringtcellreceptorfusionproteinsusingnonviralcrisprcas9genomeeditingforcancerimmunotherapy AT hudsonpeter engineeringtcellreceptorfusionproteinsusingnonviralcrisprcas9genomeeditingforcancerimmunotherapy AT leejaeyoung engineeringtcellreceptorfusionproteinsusingnonviralcrisprcas9genomeeditingforcancerimmunotherapy AT boydrichard engineeringtcellreceptorfusionproteinsusingnonviralcrisprcas9genomeeditingforcancerimmunotherapy AT trounsonalan engineeringtcellreceptorfusionproteinsusingnonviralcrisprcas9genomeeditingforcancerimmunotherapy |